Based on the well-established bispecific antibody (BsAb) develop platforms, Creative biolabs offers customized BsAb design services. We take advantages of many approaches to help customers design the expected BsAbs, including BsAbs targeting different epitopes, BsAbs targeting different ligands, BsAbs targeting different receptors and BsAbs targeting immune cells.
BsAbs have become a crucial therapeutic option for patients with cancer, inflammatory, autoimmune, and other diseases. The dual specificity of BsAbs gives them a variety of applications, such as blocking two different signaling pathways, redirecting immune cells to tumor cells, and dual targeting of different disease mediators. Nowadays, more than 60 different BsAb formats exist, some of which are being developed in the clinical pipeline. Creative biolabs are experienced in BsAb design and manufacture, we are confident in providing first class BsAbs for customers.
Figure 1. Schematic diagram of clinically investigated BsAb formats: bispecific full-length IgGs and fragment-based antibodies. (Hess, C., 2014)
BsAbs are capable of binding two or more different epitopes on one antigen or on two different antigens, which increases the functional affinity and neutralizing/activating potential of antibodies. Many diseases involve the redundant or synergistic action of disease mediators. BsAbs can target two of such mediators at the same time, block multiple pathological factors/ pathways, and improve therapeutic efficacy. Creative biolabs offers high quality BsAbs which enable to target different epitopes.
A ligand is usually referred to a molecule that can produce a signal intercellular or intracellularly by binding to a target protein (receptor). DVD-IgG, scFv-IgG, diabody, scFv-HSA fusion protein, and DART are some formats of BsAbs that have been developed to target soluble ligands in signaling pathways. Popular ligand targets include but not limit to growth factors, angiogenesis or vasculogenesis factors, and proinflammatory mediators. Creative biolabs offers high quality BsAbs which enable to target different ligands.
In the field of biology/pharmacology, a receptor is referred to a membrane protein that receives signals upon binding of signal molecules (ligands) and passes on the “message” by triggering subsequent intracellular or intercellular responses. Depending on the specific location on the membrane, receptors can be classified into three groups: cell surface receptors, cytoplasmic receptors, and nuclear receptors. Creative Biolabs can tailor BsAbs blocking these receptors to control diseases.
In recent years, scientists have gained more and more interest in the development of BsAbs that can employ immune cells to fight against different kinds of tumor or immune diseases. Specific BsAbs can retarget immune cells to tumor cells and induce anti-tumor immune responses, including T-cell mediated cell death, antibody-dependent cellular cytotoxicity (ADCC) and/or phagocytosis. Several types of BsAbs targeting T cells, NK cells and other FcR mediated effector cells are currently in clinical trials or already approved by the FDA for medical use. Bispecific T cell engagers and BiKEs (bispecific NK cell engagers) are the representatives of this type of BsAbs.
With multidisciplinary scientists, state-of-art facilities and decades of experience in antibody engineering and antibody manufacture, Creative Biolabs is dedicated to serve you with high-quality BsAbs. We also provide other various services regarding BsAbs development. Please feel free to contact us for more information and a detailed quote.
1. Fan, G.; et al. Bispecific antibodies and their applications. Journal of hematology & oncology. 2015, 8(1): 130.
2. Hess, C.; et al. Emerging classes of armed antibody therapeutics against cancer. MedChemComm. 2014, 5(4): 408-431.